 Chelsea Therapeutics International Ltds lead product candidate Northera received strong support from a US Food and Drug Administration advisory panel raising prospects the bloodpressure drug will receive approval from regulators  The FDA had rejected Northera in March  and asked Chelsea for more efficacy data on the medication It accepted the resubmitted application in September after more than a year of delays in the companys effort to bring its first treatment to market 